Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL29369942 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL10031674 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665401 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL354910 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23249 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| CN-122079850-A | Preparation method of high-purity vildagliptin intermediate and disubstituted impurity thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075511-A | Application of vildagliptin combined naringin in preparation of preparation for preventing and/or treating radiation lung injury | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079849-A | Slave dimension lattice in the mother liquor of the statin method for efficiently recycling vildagliptin | — | 2026-05-26 | — | — | CN | claimed |
| US-12624116-B2 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3634453-B1 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES | HOUSEY PHARMACEUTICAL RES LABORATORIES L L C (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| EP-1511484-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | Novartis AG (CH) | 2005-03-09 | — | — | EP | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| WO-2004052362-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| WO-2003099279-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| US-20030139434-A1 | Combinations comprising dipeptidylpeptidase-iv inhibitor | BALKAN BORK (US) | 2003-07-24 | — | — | US | claimed |
| EP-1248604-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | Novartis AG (CH) | 2002-10-16 | — | — | EP | claimed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | claimed |